Skip to main content
Account

Peer review reports

From: Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Original Submission
20 Sep 2020 Submitted Original manuscript
1 Dec 2020 Reviewed Reviewer Report
26 Dec 2020 Reviewed Reviewer Report - Ullas Batra
30 Jan 2021 Author responded Author comments - Mariano Provencio
Resubmission - Version 2
30 Jan 2021 Submitted Manuscript version 2
4 Feb 2021 Reviewed Reviewer Report - Ullas Batra
14 Feb 2021 Author responded Author comments - Mariano Provencio
Resubmission - Version 3
14 Feb 2021 Submitted Manuscript version 3
Publishing
17 Feb 2021 Editorially accepted
6 Mar 2021 Article published 10.1186/s12885-021-07922-5

Learn about peer review

Back to article page

Navigation